1. A patient with a Maddrey discriminant function (a prognostic score from prothrombin time and bilirubin) of 48 has severe alcoholic hepatitis and would ordinarily qualify for prednisolone, but on presentation has active hematemesis from a variceal bleed and new confusion. Integrating the steroid eligibility rules with the precipitant framework for hepatic encephalopathy, what is the most appropriate immediate course?
A) Start prednisolone now, because the high discriminant function overrides any contraindication
B) Withhold prednisolone and control the gastrointestinal hemorrhage first, because active bleeding is an absolute contraindication to steroids and is itself a nitrogen load that precipitates encephalopathy
C) Start prednisolone and add pentoxifylline to counteract the bleeding risk
D) Defer all therapy and recalculate the discriminant function in 7 days
E) Start prednisolone but reduce the dose by half to mitigate bleeding risk
ANSWER: B
Rationale:
Active gastrointestinal hemorrhage is an absolute contraindication to corticosteroids in severe alcoholic hepatitis, and luminal blood is simultaneously a large nitrogen load that bacteria convert to ammonia, precipitating encephalopathy; controlling the bleed therefore takes priority over steroid initiation and addresses both problems at once.
Option A: Option A is incorrect because a high discriminant function identifies steroid candidacy but never overrides an absolute contraindication such as active bleeding.
Option C: Option C is incorrect because pentoxifylline has no mortality benefit and does not counteract bleeding, and starting steroids during active hemorrhage remains contraindicated.
Option D: Option D is incorrect because deferring all therapy ignores the urgent need to control the hemorrhage and manage the precipitated encephalopathy.
Option E: Option E is incorrect because dose reduction does not convert an absolute contraindication into a safe option; steroids should be withheld until the bleeding is controlled.
2. A patient with severe alcoholic hepatitis has been on prednisolone for 7 days. The day-7 Lille score (a model predicting corticosteroid response) is 0.62, and the patient has now developed a fever with a positive blood culture. Integrating the Lille-based stopping rule with the infection risk of steroids, what is the best action?
A) Continue prednisolone for the full 28 days because stopping early forfeits benefit
B) Continue prednisolone but add a second immunosuppressant
C) Continue prednisolone and simply treat the infection without changing the steroid plan
D) Increase the prednisolone dose to overcome apparent non-response
E) Discontinue prednisolone and treat the infection, because a Lille score of 0.45 or above defines non-response with no survival benefit from continuing, and ongoing steroids would compound infection risk
ANSWER: E
Rationale:
A Lille score of 0.45 or greater at day 7 defines non-response, meaning continued prednisolone provides no survival benefit while adding cumulative immunosuppression; with a documented infection now present, discontinuing the steroid and treating the infection is the correct integration of both principles.
Option A: Option A is incorrect because completing 28 days in a defined non-responder offers no benefit and increases harm.
Option B: Option B is incorrect because adding immunosuppression in a non-responder with active infection worsens the infection risk without therapeutic gain.
Option C: Option C is incorrect because leaving the steroid unchanged ignores that non-response removes its justification and that continuation compounds infection risk.
Option D: Option D is incorrect because no Lille category calls for dose escalation, and increasing steroids during active infection is dangerous.
3. A patient with MASH (metabolic dysfunction-associated steatohepatitis) and stage F2 fibrosis is already on a moderate-intensity statin for hyperlipidemia and is now started on resmetirom. Integrating resmetirom's pharmacodynamic effect on lipids with the patient's existing statin therapy, which action is most appropriate?
A) Reassess and likely reduce the statin dose after starting resmetirom, because resmetirom independently lowers low-density lipoprotein cholesterol and may reduce statin requirements
B) Double the statin dose to counteract a resmetirom-induced rise in cholesterol
C) Stop the statin permanently because resmetirom is contraindicated with any lipid-lowering agent
D) Add a second statin to match resmetirom's mechanism
E) Make no change, because resmetirom has no effect on lipid levels
ANSWER: A
Rationale:
Resmetirom is a selective thyroid hormone receptor-beta agonist that independently lowers low-density lipoprotein cholesterol as a pharmacodynamic effect, so after initiation the existing statin should be reassessed and is often reduced because the combined lipid-lowering may exceed what is needed.
Option B: Option B is incorrect because resmetirom lowers, rather than raises, cholesterol, so dose escalation is the opposite of what is required.
Option C: Option C is incorrect because resmetirom is not contraindicated with statins; the issue is dose adjustment, not prohibition.
Option D: Option D is incorrect because adding a second statin compounds lipid lowering unnecessarily and raises toxicity risk.
Option E: Option E is incorrect because resmetirom does meaningfully reduce low-density lipoprotein cholesterol and triglycerides, so ignoring the interaction is inappropriate.
4. A patient with MASH, obesity, type 2 diabetes, and a history of heart failure with reduced ejection fraction needs metabolic therapy that may also benefit the liver. Integrating the contraindication profile of pioglitazone with the broader class benefits of glucagon-like peptide-1 (GLP-1) receptor agonists, which choice is most appropriate?
A) Pioglitazone, because its insulin-sensitizing effect is ideal for this combination of comorbidities
B) Vitamin E at high dose, because it is preferred in heart failure
C) Resmetirom, because it is approved for decompensated cirrhosis and heart failure
D) A GLP-1 receptor agonist such as semaglutide, because pioglitazone is absolutely contraindicated in heart failure while a GLP-1 agonist offers weight loss, glycemic control, and cardiovascular benefit
E) Obeticholic acid, because it treats both MASH and heart failure
ANSWER: D
Rationale:
Pioglitazone is absolutely contraindicated in heart failure because peroxisome proliferator-activated receptor-gamma agonism causes sodium retention and fluid redistribution, whereas a glucagon-like peptide-1 receptor agonist such as semaglutide provides weight loss, glycemic control, and cardiovascular benefit and has favorable MASH histological data, making it the better integrated choice.
Option A: Option A is incorrect because pioglitazone's heart-failure contraindication outweighs its metabolic appeal in this patient.
Option B: Option B is incorrect because high-dose vitamin E is not preferred in heart failure and carries its own mortality concern; it does not address the metabolic comorbidities.
Option C: Option C is incorrect because resmetirom is not approved for cirrhosis or heart failure and is restricted to fibrosis stages F2 to F3.
Option E: Option E is incorrect because obeticholic acid treats cholestatic disease, not heart failure, and can worsen hepatic decompensation.
5. A patient with primary biliary cholangitis has an inadequate biochemical response to ursodeoxycholic acid, and a prior trial of obeticholic acid was stopped because it markedly worsened an already severe pruritus. Integrating the differing effects of these agents on itch, which next step is most rational?
A) Re-challenge with a higher dose of obeticholic acid because tolerance usually develops
B) Switch to high-dose ursodeoxycholic acid at 30 mg/kg/day to improve response
C) Add bezafibrate, a peroxisome proliferator-activated receptor-alpha agonist, because it can produce a biochemical response and paradoxically improves pruritus
D) Discontinue all therapy because no further options exist
E) Start lactulose to reduce the pruritus through colonic acidification
ANSWER: C
Rationale:
Bezafibrate is a third-line peroxisome proliferator-activated receptor-alpha agonist that can produce a biochemical response in primary biliary cholangitis and paradoxically improves pruritus, making it the rational choice for a patient who is intolerant of obeticholic acid specifically because of severe itch.
Option A: Option A is incorrect because increasing obeticholic acid would worsen the very pruritus that forced its discontinuation.
Option B: Option B is incorrect because high-dose ursodeoxycholic acid is not a validated strategy for inadequate responders and is associated with harm in cholestatic disease as covered earlier.
Option D: Option D is incorrect because effective third-line therapy remains available, so abandoning treatment is premature.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and has no role in cholestatic pruritus.
6. A patient on obeticholic acid for primary biliary cholangitis shows a rising gamma-glutamyl transferase but stable bilirubin and albumin; over months they progress to Child-Pugh class B cirrhosis with new ascites. Integrating the interpretation of the enzyme change with the drug's safety boundary, what is the correct conclusion?
A) The gamma-glutamyl transferase rise alone is an expected pharmacodynamic effect, but progression to Child-Pugh B is the decisive issue, because obeticholic acid is contraindicated in decompensated cirrhosis due to a risk of hepatic decompensation, so it should be stopped
B) The gamma-glutamyl transferase rise proves hepatotoxicity, so the drug must be stopped regardless of the cirrhosis stage
C) Neither finding matters, because obeticholic acid is safe at all stages of cirrhosis
D) The drug should be continued and the dose increased to control disease progression
E) The patient should switch to high-dose ursodeoxycholic acid, which is preferred in decompensated cirrhosis
ANSWER: A
Rationale:
An isolated gamma-glutamyl transferase rise is an expected pharmacodynamic effect of obeticholic acid and does not by itself indicate hepatotoxicity, but progression to Child-Pugh class B is decisive because the drug is contraindicated in decompensated cirrhosis owing to a reported risk of hepatic decompensation, so it should be discontinued.
Option B: Option B is incorrect because the enzyme rise is not proof of hepatotoxicity; the actual reason to stop is the cirrhosis contraindication.
Option C: Option C is incorrect because obeticholic acid is not safe at all cirrhosis stages and is specifically contraindicated in Child-Pugh B or C.
Option D: Option D is incorrect because increasing the dose in decompensated cirrhosis heightens the decompensation risk.
Option E: Option E is incorrect because high-dose ursodeoxycholic acid is not preferred in decompensated cirrhosis and is harmful in the cholestatic settings discussed.
7. A patient with primary sclerosing cholangitis (PSC) and coexisting ulcerative colitis asks why they are not being offered the same drug ladder used in primary biliary cholangitis. Integrating the contrasting evidence base between the two diseases, which response is most accurate?
A) The same ursodeoxycholic acid, obeticholic acid, and bezafibrate ladder applies equally to PSC
B) High-dose ursodeoxycholic acid is the proven disease-modifying therapy unique to PSC
C) Obeticholic acid halts fibrosis in PSC just as it improves biochemistry in primary biliary cholangitis
D) PSC requires no surveillance because the drug options are identical
E) Unlike primary biliary cholangitis, PSC has no pharmacological agent proven to halt fibrosis or improve transplant-free survival; high-dose ursodeoxycholic acid is harmful, so management centers on stricture treatment, cancer surveillance, and transplant evaluation
ANSWER: E
Rationale:
Primary biliary cholangitis has a sequential evidence-based drug ladder, whereas primary sclerosing cholangitis has no pharmacological agent proven to halt fibrosis or improve transplant-free survival, high-dose ursodeoxycholic acid is actively harmful, and management therefore centers on endoscopic treatment of dominant strictures, cholangiocarcinoma and colorectal cancer surveillance, and timely transplant evaluation.
Option A: Option A is incorrect because the primary biliary cholangitis ladder does not transfer to PSC, where those agents lack proven benefit.
Option B: Option B is incorrect because high-dose ursodeoxycholic acid is harmful in PSC, not a proven therapy.
Option C: Option C is incorrect because obeticholic acid is not shown to halt fibrosis in PSC.
Option D: Option D is incorrect because PSC in fact demands intensive surveillance for cholangiocarcinoma and, with concurrent colitis, colorectal cancer.
8. A cirrhotic patient on lactulose and aggressive diuresis becomes encephalopathic; labs show hypokalemia and a metabolic alkalosis. Integrating the acid-base chemistry of ammonia with the precipitant framework, what is the most appropriate management priority?
A) Increase lactulose to the maximum dose and continue the current diuretic regimen unchanged
B) Correct the hypokalemia and metabolic alkalosis and reduce the diuretic, because an alkaline pH shifts the equilibrium toward diffusible ammonia that crosses the blood-brain barrier
C) Stop lactulose, since the electrolyte problem makes it ineffective
D) Add a systemic benzodiazepine for agitation while continuing diuresis
E) Administer additional potassium-wasting diuretics to enhance ammonia excretion
ANSWER: B
Rationale:
Hypokalemia and metabolic alkalosis are recognized precipitants of encephalopathy because an alkaline pH shifts the ammonium-ammonia equilibrium toward un-ionized, diffusible ammonia that crosses the blood-brain barrier, so correcting the potassium and the alkalosis and reducing the offending diuretic addresses the actual driver.
Option A: Option A is incorrect because escalating lactulose while leaving the precipitating electrolyte and acid-base disturbance uncorrected fails to address the cause.
Option C: Option C is incorrect because lactulose remains beneficial and should not be stopped; the electrolyte disturbance is corrected alongside it.
Option D: Option D is incorrect because benzodiazepines are potent precipitants of encephalopathy and would worsen the patient.
Option E: Option E is incorrect because more potassium-wasting diuresis deepens the hypokalemia and alkalosis, intensifying the precipitant.
9. A patient treated for hepatic encephalopathy is having eight watery stools daily and has become more confused, with new hypernatremia and clinical dehydration. Integrating the dosing target of lactulose with its potential to precipitate encephalopathy, what is the best adjustment?
A) Increase lactulose further, since more stooling always lowers ammonia
B) Add a second osmotic laxative to accelerate transit
C) Stop lactulose entirely and rely on rifaximin alone
D) Reduce the lactulose dose to target two to three soft stools per day and correct the dehydration and hypernatremia, because over-purging causes fluid and electrolyte disturbances that themselves precipitate encephalopathy
E) Maintain the current dose and restrict free water to manage the hypernatremia
ANSWER: D
Rationale:
Lactulose is titrated to two to three soft stools daily; over-purging beyond four stools produces dehydration and hypernatremia, which are themselves precipitants of encephalopathy, so the correct step is to reduce the dose to the target and correct the fluid and electrolyte disturbance.
Option A: Option A is incorrect because more stooling is not uniformly beneficial and the excessive purging is the cause of the deterioration.
Option B: Option B is incorrect because adding another laxative worsens the over-purging and the dehydration.
Option C: Option C is incorrect because stopping lactulose abandons effective therapy when the real problem is over-titration that can simply be reduced.
Option E: Option E is incorrect because maintaining excessive purging and only restricting water does not address the volume depletion driving the hypernatremia and confusion.
10. A patient who recovered from a first hospitalization for overt hepatic encephalopathy was discharged on lactulose alone and now returns 6 weeks later with a second overt episode despite good adherence and no identifiable new precipitant. Integrating the evidence on combination therapy with the principle of secondary prophylaxis, what is the best long-term adjustment?
A) Replace lactulose with rifaximin monotherapy
B) Replace lactulose with a systemic antibiotic such as neomycin
C) Add rifaximin to the ongoing lactulose, because the combination is superior to either agent alone for preventing recurrence and rifaximin is add-on rather than replacement therapy
D) Stop lactulose and observe, since adherence is already good
E) Add a benzodiazepine to manage future episodes prophylactically
ANSWER: C
Rationale:
After an episode of overt encephalopathy, rifaximin is added to ongoing lactulose for secondary prophylaxis, and the combination is superior to either agent alone; this patient on lactulose alone who has recurred should have rifaximin added rather than substituted.
Option A: Option A is incorrect because rifaximin is add-on therapy, not a monotherapy replacement for lactulose.
Option B: Option B is incorrect because a systemic antibiotic introduces systemic toxicity and resistance concerns that the non-absorbed rifaximin avoids, and replacing lactulose removes its benefit.
Option D: Option D is incorrect because stopping effective therapy after a recurrence invites further episodes.
Option E: Option E is incorrect because benzodiazepines precipitate encephalopathy and have no prophylactic role.
11. A patient on resmetirom for MASH with F3 fibrosis is started on rifampin for a latent tuberculosis regimen. Integrating resmetirom's metabolic pathway with the pharmacokinetic effect of rifampin, what is the most likely consequence and the appropriate response?
A) Rifampin, a strong CYP3A4 (cytochrome P450 3A4) inducer, will lower resmetirom exposure and reduce its efficacy, so the strong inducer should be avoided or an alternative regimen sought
B) Rifampin will raise resmetirom levels to toxic concentrations, so resmetirom should be halved
C) There is no interaction, because resmetirom is not metabolized by cytochrome P450 enzymes
D) Rifampin will convert resmetirom into a more active metabolite, improving efficacy
E) Resmetirom will block rifampin metabolism, causing rifampin toxicity
ANSWER: A
Rationale:
Resmetirom is a substrate of CYP3A4, so co-administration with the strong inducer rifampin accelerates resmetirom metabolism, lowering its exposure and reducing efficacy; strong CYP3A4 inducers should therefore be avoided, and an alternative approach to the tuberculosis regimen or resmetirom should be sought.
Option B: Option B is incorrect because an inducer lowers, not raises, substrate levels, so dose reduction is the wrong direction.
Option C: Option C is incorrect because resmetirom is in fact a CYP3A4 substrate, so the interaction is real.
Option D: Option D is incorrect because induction increases clearance of resmetirom rather than generating a more active metabolite.
Option E: Option E is incorrect because the interaction runs through induction of resmetirom metabolism, not resmetirom inhibiting rifampin.
12. A complex patient has both MASH with F2 fibrosis and primary biliary cholangitis with inadequate ursodeoxycholic acid response. A trainee is mapping the receptor targets of the agents under consideration. Integrating the nuclear-receptor pharmacology across these conditions, which mapping correctly links each drug to its receptor and principal hepatic consequence?
A) Resmetirom acts at the farnesoid X receptor to suppress bile acid synthesis; pioglitazone acts at the thyroid hormone receptor-beta to oxidize fat
B) Obeticholic acid acts at peroxisome proliferator-activated receptor-gamma to sensitize insulin; resmetirom acts at the farnesoid X receptor
C) Pioglitazone acts at the thyroid hormone receptor-beta to lower low-density lipoprotein; obeticholic acid acts at peroxisome proliferator-activated receptor-gamma
D) All three drugs act at the farnesoid X receptor with identical hepatic effects
E) Resmetirom acts at the thyroid hormone receptor-beta to increase hepatic fatty acid oxidation; pioglitazone acts at peroxisome proliferator-activated receptor-gamma to improve insulin sensitivity; obeticholic acid acts at the farnesoid X receptor to suppress bile acid synthesis
ANSWER: E
Rationale:
Resmetirom is a thyroid hormone receptor-beta agonist that increases hepatic fatty acid oxidation, pioglitazone is a peroxisome proliferator-activated receptor-gamma agonist that improves insulin sensitivity, and obeticholic acid is a farnesoid X receptor agonist that suppresses bile acid synthesis; only this option links each drug to its correct receptor and hepatic consequence.
Option A: Option A is incorrect because it swaps the targets of resmetirom and pioglitazone.
Option B: Option B is incorrect because obeticholic acid is not a peroxisome proliferator-activated receptor-gamma agonist and resmetirom is not a farnesoid X receptor agonist.
Option C: Option C is incorrect because pioglitazone is not a thyroid hormone receptor agonist and obeticholic acid is not a peroxisome proliferator-activated receptor-gamma agonist.
Option D: Option D is incorrect because the three drugs act at three distinct receptors with different effects, not a single shared receptor.
13. A patient presents with suspected severe alcoholic hepatitis. Integrating the roles of the Maddrey discriminant function, contraindication screening, and the Lille model into a single coherent pathway, which sequence of decisions is correct?
A) Start steroids empirically, then calculate the Maddrey function at day 7 to confirm severity, then check the Lille score at day 28
B) Calculate the Maddrey discriminant function to identify severe disease, screen for absolute contraindications such as infection or active bleeding before starting prednisolone, then assess the Lille score at day 7 to decide whether to continue or stop
C) Check the Lille score at admission to select candidates, then calculate the Maddrey function at day 7 to decide continuation, ignoring contraindications
D) Treat all patients with 28 days of steroids regardless of scoring or contraindications, then calculate scores afterward
E) Screen for contraindications only after completing the full 28-day steroid course
ANSWER: B
Rationale:
The correct pathway uses the Maddrey discriminant function to identify severe disease, then screens for absolute contraindications such as active infection or bleeding before initiating prednisolone, and then uses the day-7 Lille score to decide whether to continue or discontinue therapy.
Option A: Option A is incorrect because the Maddrey function is a baseline severity tool used before treatment, not a day-7 confirmation, and steroids should not be started before contraindication screening.
Option C: Option C is incorrect because the Lille score is a day-7 response measure rather than an admission selection tool, and contraindications must never be ignored.
Option D: Option D is incorrect because treating everyone without scoring or contraindication screening exposes patients to harm and ignores the Lille stopping rule.
Option E: Option E is incorrect because contraindication screening must precede, not follow, steroid initiation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.